Research reveals that around 20 per cent of all cases of the most severe form of breast cancer may arise from the small group of normal tissue cells carrying an epimutation of a specific gene.
Enara Bio’s $32.5M Series B to support lead dark antigen program for GI cancers
Enara Bio has snagged $32.5 million in a Series B fundraise, backed in part by Pfizer’s venture arm, to help develop a preclinical pipeline of
October 4, 2024